IL1B and diabetes mellitus: In this current study, we determined that administering one weekly 100 μL subcutaneous injection of saline containing 20 μM of XMD8-92 was sufficient to ameliorate diabetes-mediated IL-6 and VEGF production, and significantly decreased IL-1β in diabetic mice.